the effect of immunomodulators on the immunogenicity of tnf-blocking therapeutic monoclonal antibodies a review的效果免疫调制剂对肿瘤坏死因子抑制剂中治疗性单克隆抗体的免疫原性审查.pdfVIP

the effect of immunomodulators on the immunogenicity of tnf-blocking therapeutic monoclonal antibodies a review的效果免疫调制剂对肿瘤坏死因子抑制剂中治疗性单克隆抗体的免疫原性审查.pdf

  1. 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
  2. 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  3. 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  4. 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  5. 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  6. 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  7. 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
the effect of immunomodulators on the immunogenicity of tnf-blocking therapeutic monoclonal antibodies a review的效果免疫调制剂对肿瘤坏死因子抑制剂中治疗性单克隆抗体的免疫原性审查

Krieckaert et al. Arthritis Research Therapy 2010, 12:217 /content/12/5/217 R E V I E W The ef ect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review 1 1 2 1 Charlotte Louise Maria Krieckaert* , Geertje Margret Bartelds , Willem Frederik Lems and Gerrit Jan Wolbink standard ization of the assays used to measure anti-TmAb Abstract anti bodies, and the timing of the measurements make Therapeutic monoclonal antibodies have immunogenicity a complex subject to investigate. Several revolutionized the treatment of various inl ammatory studies in various infl ammatory diseases demonstrate the diseases. Immunogenicity against these antibodies presence of anti-TmAb antibodies [1]. Table 1 gives an has been shown to be clinically important: it is overview of the reported frequency of anti-TmAb associated with shorter response duration because antibodies in infl ixi mab (antibodies to infl iximab, or of diminishing concentrations in the blood and with ATIs) and in adali mumab (anti-adalimumab antibodies, infusion reactions. Concomitant immunomodulators or AAAs) [2-22]. h e large variation in the percentages of in the form of methotrexate or azathioprine reduced anti-TmAb antibodies measured could be related to the the immunogenicity of therapeutic antibodies in diff erences in assays, duration of treatment, and the use rheumatoid arthritis, Cro

您可能关注的文档

文档评论(0)

118zhuanqian + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档